Evidence map›Paper›PMID 28358435›Full record

ArticleOncology reports2017

Clinical significance of T cell clonality and expression levels of immune-related genes in endometrial cancer.

Yuji Ikeda, Kazuma Kiyotani, Poh Yin Yew, Sho Sato, Yuichi Imai, Rui Yamaguchi, Satoru Miyano, Keiichi Fujiwara, Kosei Hasegawa, Yusuke Nakamura

Open access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Yuji IkedaSection of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL 60637, USA.
Kazuma KiyotaniSection of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL 60637, USA.
Poh Yin YewSection of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL 60637, USA.
Sho SatoDepartment of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 3501298, Japan.
Yuichi ImaiDepartment of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 3501298, Japan.
Rui YamaguchiHuman Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 1088639, Japan.
Satoru MiyanoHuman Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 1088639, Japan.
Keiichi FujiwaraDepartment of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 3501298, Japan.
Kosei HasegawaDepartment of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 3501298, Japan.
Yusuke NakamuraSection of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL 60637, USA.
Saitama Medical University · JPUniversity of Chicago · USThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune microenvironment characterized by T cell clonality as well as expression signatures of immune-related genes in endometrial cancer tissues may play significant roles in clinical outcome of patients. We aimed to investigate the clinical significance of immune-related gene expression and TCR repertoire in endometrial cancer. Using total RNAs extracted from 32 endometrioid endometrial cancer cases, we performed quantitative real-time PCR to measure mRNA expression levels of immune-related genes including TRB, CD8, GZMA, HLA-A, CD11c and PD-L1. Higher mRNA expression levels of CD8 (P=0.039) and CD11c (P=0.046) in the 32 tissue samples were significantly associated with longer progression-free survival (PFS). Expression levels of CD8 (P<0.001) and CD11c (P=0.048) were also significantly associated with longer PFS in 540 cases in TCGA database. We also performed T cell receptor β (TCRβ) sequencing of tumor-infiltrating lymphocytes (TILs) on an Illumina MiSeq platform. To evaluate clonal expansion of TCRβ clonotypes, we adjusted the number of abundant TCRβ clonotypes by TRB mRNA expression levels and examined TCR clonality with the expression levels of immune-related genes and clinicopathological factors. The cases with high clonal T cell expansion along with high PD-L1 expression in cancer tissues was related to higher mRNA expression levels of CD8 (P<0.001), GZMA (P<0.001) and HLA-A (P=0.027), showed a significantly longer PFS (P=0.015), indicating a possibility that these parameters may serve as faborable prognostic factors. Considering clinical stage, mRNA expression of CD8 (P=0.037), GZMA (P=0.027) and HLA-A (P=0.022) was significantly higher in tumors at an early stage. Thus, we identified clinical and prognostic significance of immune microenvironment including the T cell clonality of TILs as well as PD-L1 and CD11c mRNA expression levels in endometrial cancer tissues.

Indexed as

AdultAgedBiomarkers, TumorCD11c AntigenCD8 AntigensEndometrial NeoplasmsFemaleGene Expression Regulation, NeoplasticGranzymesHumansKaplan-Meier EstimateLymphocytes, Tumor-InfiltratingMiddle AgedPrognosisReceptors, Antigen, T-Cell, alpha-betaBiomarkers, TumorCD11c AntigenCD8 AntigensGranzymesGZMA protein, humanReceptors, Antigen, T-Cell, alpha-beta

Identifiers

PMID28358435
PMCPMC5428285
OpenAlexW2597537649

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.